Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Clinical trials sponsored by Shenzhen Fosun Kairos Biotechnology Co., Ltd., explained in plain language.
A subsidiary of Fosun Pharma focused on biologics and biosimilars.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma Results expected Nov 2026 (estimated)
-
Can engineered immune cells tackle a tough kidney disease?
Cure Not yet recruitingThis trial is testing an experimental therapy called FKC289 for people with a type of kidney disease called primary membranous nephropathy that has come back or not responded to standard treatment. FKC289 uses the patient's own immune cells, which are modified in the lab to recog…
Phase 1/2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take aim at a rare Protein-Folding disease
Cure Not yet recruitingThis trial is testing an experimental treatment called FKC289 for people with primary AL amyloidosis that has relapsed or not responded to standard care. FKC289 uses a patient's own immune cells, engineered to recognize and attack the abnormal plasma cells that produce the harmfu…
Phase 1/2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC